Company news

Recursion Pharmaceuticals, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Recursion to Host Webinar Focused on Updated REC-4881 (FAP) Data from CGA-IGC on Tuesday, November 3

October 26, 2026

Recursion Announces Sanofi Options Potential First-in-Class Immunology Development Candidate from Their Collaboration

October 15, 2026

Recursion Announces Pricing of $200 Million Underwritten Offering of Class A Common Stock

October 15, 2026

Recursion Announces $200 Million Oversubscribed Follow-On Offering, Clinical Data Updates, and Partnership Milestone

October 15, 2026

Recursion Reports Second Quarter Financial Results; Genentech Options First Neuroscience Target into Early Discovery Program

August 5, 2026

Recursion to Report Second Quarter 2026 Business Updates and Financial Results on August 5th

July 29, 2026

Remix Therapeutics to Present at AACR Drug Discovery and Development Conference

July 16, 2026

Recursion Reports First Quarter Financial Results and Provides Business Update

May 6, 2026

Recursion Announces Board Transition

April 30, 2026

Recursion to Report First Quarter 2026 Business Updates and Financial Results on May 6

April 28, 2026

Recursion Expands Strategic Partnership with Citeline to Advance Its AI-Enabled ClinTech Platform

March 31, 2026

Recursion Announces Vicki Goodman, M.D., as Incoming Chief Medical Officer

March 24, 2026

PacBio Announces the Appointment of Chris Gibson to the Board of Directors

March 5, 2026

Recursion Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

February 25, 2026

Recursion To Be Featured in HighRes’ Lightning Talk at NVIDIA GTC

February 23, 2026

Recursion to Report Fourth Quarter and Full Year 2025 Business Updates and Financial Results on February 25

February 18, 2026

Recursion Reports Grant of Inducement Awards as Permitted by the Nasdaq Listing Rules

February 12, 2026

Recursion to Present at 44th Annual J.P. Morgan Healthcare Conference

January 5, 2026

Positive Phase 1b/2 Results from Ongoing REC-4881 TUPELO Trial Demonstrate Rapid and Durable Reductions in Polyp Burden in Familial Adenomatous Polyposis (FAP) at 25 Weeks

December 7, 2025

Recursion Announces Webinar For Upcoming Clinical Data Readout on the TUPELO Phase 1b/2 Trial of REC-4881 in Familial Adenomatous Polyposis on December 8, 2025

November 30, 2025

Recursion Reports Third Quarter 2025 Financial Results and Provides Business Update

November 4, 2025

Recursion Announces CEO Transition Plan to Drive Next Phase of Growth

November 4, 2025

Recursion to Participate in Upcoming Investor Conferences

November 3, 2025

Recursion to Report Third Quarter 2025 Business Updates and Financial Results on November 5th

October 27, 2025

Rallybio Reports Second Quarter 2025 Financial Results and Provides Business Updates

August 7, 2025

Recursion Reports Second Quarter 2025 Financial Results and Provides Business Update

August 4, 2025

Recursion to Report Second Quarter 2025 Business Updates and Financial Results on August 5th

July 28, 2025

Recursion Acquires Full Rights to REV102, a Potential First-in-Class Oral ENPP1 Inhibitor for Hypophosphatasia

July 7, 2025

MIT and Recursion Release Boltz-2: Next Generation AI Model to Predict Binding Affinity at Unprecedented Speed, Scale, and Accuracy

June 5, 2025

Recursion Reports First Quarter 2025 Financial Results and Provides Business Update

May 4, 2025

Preliminary Phase 1b/2 Data for REC-4881 in Familial Adenomatous Polyposis (FAP) Demonstrates Reduced Polyp Burden

May 3, 2025

Recursion to Report First Quarter 2025 Business Updates and Financial Results on May 5th

April 27, 2025

Recursion to Present Preliminary Clinical Data from the Ongoing Phase 1b/2 trial of REC-4881 in FAP at Digestive Disease Week 2025

April 21, 2025

Recursion and Enamine Release New AI-Enabled Targeted Compound Libraries

April 8, 2025

Recursion Announces First Patient Dosed in Phase 1 Clinical Study of REC-3565, a Selective MALT1 Inhibitor for Relapsed or Refractory B-cell Lymphomas

April 7, 2025

Recursion to Participate in Upcoming Investor Conference

March 31, 2025

Recursion Bolsters Board of Directors with Former FDA Principal Deputy Commissioner Dr. Namandjé Bumpus and Mammoth Biosciences COO and CFO Elaine Sun

March 17, 2025

Recursion Provides Business Updates and Reports Fourth Quarter and Fiscal Year 2024 Financial Results

February 27, 2025

Recursion to Report Fourth Quarter and Fiscal Year 2024 Business Updates and Financial Results on February 28th

February 23, 2025

Recursion Presents Phase 2 Data for REC-994 in CCM in Late-Breaking Oral Presentation at the International Stroke Conference

February 4, 2025

Recursion Announces Two Key Investigational Oncology Drugs Advancing to Clinical Trials, Targeting High Unmet Needs in Hematologic Malignancies, Small-Cell Lung Cancer, & More

January 6, 2025

Recursion to Present at 43rd Annual JP Morgan Healthcare Conference

January 5, 2025

Recursion Pharmaceuticals Reports Grant of Inducement Awards as Permitted by the Nasdaq Listing Rules

December 19, 2024

Recursion Reports Interim Phase 1 Clinical Data for REC-617 Monotherapy, a Potential Best-in-Class CDK7 Inhibitor, With Encouraging Patient Response and Favorable Tolerability

December 8, 2024

Recursion announces first patient dosed in Phase 1/2 clinical study of REC-1245, a potential first-in-class, RBM39 degrader for Biomarker-Enriched Solid Tumors and Lymphoma

December 2, 2024

Recursion and Exscientia, two leaders in the AI drug discovery space, have officially combined to advance the industrialization of drug discovery

November 19, 2024

Recursion and Exscientia Shareholders Approve the Proposed Combination

November 12, 2024

Recursion Announces the Release of OpenPhenom-S/16 in Google Cloud’s Model Garden

November 11, 2024

Recursion Provides Business Updates and Reports Third Quarter 2024 Financial Results

November 5, 2024

Recursion to Report Third Quarter 2024 Business Updates and Financial Results on November 6th

October 29, 2024

Older news releases →

Calls

The 5 newest of 9 calls. Every call is listed under its year.

Decks

The 5 newest of 47 decks. Every deck is listed under its year.